ReviewJournal of autoimmunity
Why can't we find a new treatment for SLE?
Review in Journal of autoimmunity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.Rheumatology (Oxford, England) · 2014Trial
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Annals of the rheumatic diseases · 2014Trial
- Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.Arthritis and rheumatism · 2013Trial
- Double humanised lupus mouse model with human immune system and faecal microbiota from patients with SLE.Lupus science & medicine · 2026Article
- Quality Care Assessment in Gout.Current rheumatology reports · 2025Review
- Altered Hippocampal and Striatal Expression of Endothelial Markers and VIP/PACAP Neuropeptides in a Mouse Model of Systemic Lupus Erythematosus.International journal of molecular sciences · 2023Article
- Mechanistic Paradigms of Natural Plant Metabolites as Remedial Candidates for Systemic Lupus Erythromatosus.Cells · 2020Review
- The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus.Current rheumatology reports · 2019Review
- Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice.Scientific reports · 2017Article
- Article
- Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.Frontiers in immunology · 2015Review
- Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.Lupus science & medicine · 2015Article
- VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus.Immunology · 2014Article
- Aicardi-Goutières syndrome: a model disease for systemic autoimmunity.Clinical and experimental immunology · 2014Review
- The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey.Rheumatology (Oxford, England) · 2013Article
- Activation-induced deaminase contributes to the antibody-independent role of B cells in the development of autoimmunity.Autoimmunity · 2012Article
- Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study.PloS one · 2012Article
- Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rγ-/- mice: a promising model for studying human disease.Arthritis and rheumatism · 2011Article
- Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.Molecular & cellular proteomics : MCP · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
No new therapy for systemic lupus erythematosus has been approved. In the last decade, the development of several novel compounds has been pursued for lupus, but so far nothing has been proven to be effective. This review discusses some of the reasons why it may be so difficult to demonstrate that a novel therapy is effective for this disease. These include the complexity of the disease itself; the lack of reliable outcome measures; our limited understanding of the pathogenesis of the disease; the propensity of lupus patients to have bad outcomes and to react to medicines in unusual ways; the heterogeneity of the patient population; the unpredictable course of disease in individual patients; and the lack of reliable biomarkers. Although some of the tested targeted compounds that are apparently based on strong preclinical and mechanistic data may indeed not be effective therapies for SLE, it is hard not to believe that among the various specific agents now being tested that at least some of them should downregulate the abnormal immunoregulation characteristic of SLE, and thus be clinically effective. We need to be persistent and imaginative in identifying these effective agents and proving their efficacy so that they may be widely used in our lupus populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.